References

  1. 1.Smith PEM. Initial management of seizure in adults. N Engl J Med. 2021;385(3):251-263.
  2. 2.Jiménez-Villegas MJ, et al. Update on first unprovoked seizure in children and adults: a narrative review. Seizure. 2021;90:28-33.
  3. 3.Kobau R, et al. Active epilepsy prevalence among U.S. adults is 1.1% and differs by educational level-National Health Interview Survey, United States, 2021. Epilepsy Behav. 2023;142:109180.
  4. 4.Kaur S, et al. Adult onset seizures: clinical, etiological, and radiological profile. J Family Med Prim Care. 2018;7(1):191-197.
  5. 5.Fisher RS, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475-482.
  6. 6.Mauritz M, et al. Acute symptomatic seizures: an educational, evidence-based review. Epileptic Disord. 2022;24(1):26-49.
  7. 7.Krumholz A, et al. Evidence-based guideline: management of an unprovoked first seizure in adults: report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2015;84(16):1705-1713.
  8. 8.Lee RK, et al. ACR Appropriateness Criteria® seizures and epilepsy. J Am Coll Radiol. 2020;17(5):S293-S304.
  9. 9.Joelsson S, et al. Diagnostic value of EEG after a first unprovoked seizure in adults. Epilepsy Behav. 2025;162:110151.
  10. 10.Trinka E, et al. A definition and classification of status epilepticus—report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56(10):1515-1523.
  11. 11.Levi-Abayo S, et al. Guidelines and epilepsy practice: antiseizure medication initiation following an unprovoked first seizure in adults. Epilepsy Res. 2024;200:107304.
  12. 12.Tolchin B, et al.; Ethics, Law, and Humanities Committee; and for the American Epilepsy Society and the Epilepsy Foundation of America. Seizures, driver licensure, and medical reporting update: an AAN position statement. Neurology. 2025;104(7):e213459.
  13. 13.Epilepsy Foundation. Driving laws: driving information by state. https://www.epilepsy.com/lifestyle/driving-and-transportation/laws​
  1. 1.Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475-482.
  2. 2.Fiest KM, Sauro KM, Wiebe S, et al. Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies. Neurology. 2017;88(3):296-303.
  3. 3.Asadi-Pooya AA, Brigo F, Lattanzi S, et al. Adult epilepsy. Lancet. 2023;402(10399):412-424.
  4. 4.Mbizvo GK, Bennett K, Simpson CR, et al. Epilepsy-related and other causes of mortality in people with epilepsy: a systematic review of systematic reviews. Epilepsy Res. 2019;157:106192.
  5. 5.Smith PEM. Initial management of seizure in adults. N Engl J Med. 2021;385(3):251-263.
  6. 6.Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):512-521.
  7. 7.Giuliano L, Cicero CE, Trimarchi G, et al. Usefulness of a smartphone application for the diagnosis of epilepsy: validation study in high-income and rural low-income countries. Epilepsy Behav. 2021;115:107680.
  8. 8.Milligan TA. Epilepsy: a clinical overview. Am J Med. 2021;134(7):840-847.
  9. 9.Beniczky S, Trinka E, Wirrell E, et al. Updated classification of epileptic seizures: position paper of the International League Against Epilepsy. Epilepsia. 2025;66(6):1804-1823.
  10. 10.Leibetseder A, Eisermann M, LaFrance WC Jr, et al. How to distinguish seizures from non-epileptic manifestations. Epileptic Disord. 2020;22(6):716-738.
  11. 11.Devinsky O, Hesdorffer DC, Thurman DJ, et al. Sudden unexpected death in epilepsy: epidemiology, mechanisms, and prevention. Lancet Neurol. 2016;15(10):1075-1088.
  12. 12.Ebong I, Haghighat Z, Bensalem-Owen M. Approach to loss of consciousness: distinguishing epileptic seizures, psychogenic nonepileptic seizures, and syncope. Semin Neurol. 2021;41(6):667-672.
  13. 13.Webb J, Long B, Koyfman A. An emergency medicine–focused review of seizure mimics. J Emerg Med. 2017;52(5):645-653.
  14. 14.Benbadis S. The differential diagnosis of epilepsy: a critical review. Epilepsy Behav. 2009;15(1):15-21.
  15. 15.Rowland K, Lambert CE Jr. Evaluation after a first seizure in adults. Am Fam Physician. 2022;105(5):507-513.
  16. 16.Amarenco P. Transient ischemic attack. N Engl J Med. 2020;382(20):1933-1941.
  17. 17.Feyissa AM, Bower JH. Evaluation of the patient with paroxysmal spells mimicking epileptic seizures. Neurologist. 2023;28(4):207-217.
  18. 18.Thijs RD, Surges R, O’Brien TJ, et al. Epilepsy in adults. Lancet. 2019;393(10172):689-701.
  19. 19.Crompton DE, Berkovic SF. The borderland of epilepsy: clinical and molecular features of phenomena that mimic epileptic seizures. Lancet Neurol. 2009;8(4):370-381.
  20. 20.Amin U, Benbadis SR. The role of stand-alone videos in the diagnosis of seizures. Epilepsy Behav. 2024;153:109673.
  1. 1.Krumholz A, Wiebe S, Gronseth GS, et al. Evidence-based guideline: management of an unprovoked first seizure in adults: report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2015;84(16):1705-1713.
  2. 2.Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475-482.
  3. 3.Brigo F, Marson A. Approach to the medical treatment of epilepsy. Continuum (Minneap Minn). 2022;28(2):483-499.
  4. 4.Beniczky S, Asadi-Pooya AA, Perucca E, et al. A web-based algorithm to rapidly classify seizures for the purpose of drug selection. Epilepsia. 2021;62(10):2474-2484.
  5. 5.Bauer D, Quigg M. Optimizing management of medically responsive epilepsy. Continuum (Minneap Minn). 2019;25(2):343-361.
  6. 6.Abou-Khalil BW. Update on antiseizure medications 2025. Continuum (Minneap Minn). 2025;31(1):125-164.
  7. 7.Sen A, Jette N, Husain M, et al. Epilepsy in older people. Lancet. 2020;395(10225):735-748.
  8. 8.Brigo F, Broggi S, Lattanzi S. Withdrawal of antiseizure medications - for whom, when, and how?. Expert Rev Neurother. 2023;23(4):311-319.
  9. 9.Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069-1077.
  10. 10.Löscher W, Potschka H, Sisodiya SM, et al. Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options. Pharmacol Rev. 2020;72(3):606-638.
  11. 11.Bloom R, Amber KT. Identifying the incidence of rash, Stevens-Johnson syndrome and toxic epidermal necrolysis in patients taking lamotrigine: a systematic review of 122 randomized controlled trials. An Bras Dermatol. 2017;92(1):139-141.
  12. 12.West S, Nevitt SJ, Cotton J, et al. Surgery for epilepsy. Cochrane Database Syst Rev. 2019(6):CD010541.
  13. 13.Ryvlin P, Rheims S, Hirsch LJ, et al. Neuromodulation in epilepsy: state-of-the-art approved therapies. Lancet Neurol. 2021;20(12):1038-1047.
  14. 14.Panebianco M, Rigby A, Marson AG. Vagus nerve stimulation for focal seizures. Cochrane Database Syst Rev. 2022(7):CD002896.
  15. 15.Tomson T, Battino D, Bonizzoni E, et al.; EURAP Study Group. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018;17(6):530-538.
  16. 16.Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012;11(9):792-802.
  17. 17.Devinsky O, Cross JH, Laux L, et al.; Cannabidiol in Dravet Syndrome Study Group. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011-2020.
  18. 18.Thiele EA, Marsh ED, French JA, et al.; GWPCARE4 Study Group. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085-1096.
  19. 19.McDonald TJW, Cervenka MC. Ketogenic diets for adults with highly refractory epilepsy. Epilepsy Curr. 2017;17(6):346-350.
  20. 20.Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American Epilepsy Society. Epilepsy Curr. 2016;16(1):48-61.
  21. 21.Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus—report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56(10):1515-1523.
  22. 22.Levenson M, Rochester CG, Mentari E, et al. Statistical Review and Evaluation: Antiepileptic Drugs and Suicidality. LevensonMRochesterCGMentariEet al. Statistical Review and Evaluation: Antiepileptic Drugs and Suicidality. U.S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research; Office of Translational Sciences; Office of Biostatistics; 2008.
  23. 23.US Food and Drug Administration. Suicidality and antiepileptic Drugs: an FDA alert. https://www.sfda.gov.sa/en/warnings/1175​
  24. 24.Meador KJ, Baker GA, Browning N, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study). Lancet Neurol. 2013;12(3):244-252.
  25. 25.Pennell PB. Use of antiepileptic drugs during pregnancy: evolving concepts. Neurotherapeutics. 2016;13(4):811-820.
  26. 26.Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428(6982):486.
  27. 27.Lamberink HJ, Otte WM, Geerts AT, et al. Individualised prediction model of seizure recurrence and long-term outcomes after withdrawal of antiepileptic drugs in seizure-free patients: a systematic review and individual participant data meta-analysis. Lancet Neurol. 2017;16(7):523-531.
  28. 28.US Food and Drug Administration. Information for healthcare professionals: dangerous or even fatal skin reactions—carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics). https://ia601504.us.archive.org/12/items/www.fda.gov/www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124718.htm​
  29. 29.Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006;61(3):246-255.
  30. 30.Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. Ther Drug Monit. 2018;40(5):526-548.
  31. 31.French JA. Refractory epilepsy: clinical overview. Epilepsia. 2007;48:3-7.
  32. 32.Wiebe S, Blume WT, Girvin JP, et al.; Effectiveness and Efficiency of Surgery for Temporal Lobe Epilepsy Study Group. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med. 2001;345(5):311-318.
  33. 33.Engel J Jr, McDermott MP, Wiebe S, et al.; Early Randomized Surgical Epilepsy Trial (ERSET) Study Group. Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. JAMA. 2012;307(9):922-930.
  34. 34.Brodie MJ, Barry SJE, Bamagous GA, et al. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012;78(20):1548-1554.
  1. 1.Asadi-Pooya AA, Brigo F, Lattanzi S, et al. Adult epilepsy. Lancet. 2023;402(10399):412-424.
  2. 2.Lado FA, Ahrens SM, Riker E, et al.; National Association of Epilepsy Guidelines for Specialized Epilepsy Centers Panel. Guidelines for specialized epilepsy centers: executive summary of the report of the National Association of Epilepsy Centers Guideline Panel. Neurology. 2024;102(4):e208087.
  3. 3.Whitney R, Jones KC, Sharma S, et al. SUDEP counseling: where do we stand?. Epilepsia. 2023;64(6):1424-1431.
  4. 4.Harden C, Tomson T, Gloss D, et al. Practice guideline summary: sudden unexpected death in epilepsy incidence rates and risk factors: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsy Curr. 2017;17(3):180-187.
  5. 5.Maguire MJ, Jackson CF, Marson AG, et al. Treatments for the prevention of sudden unexpected death in epilepsy (SUDEP). Cochrane Database Syst Rev. 2020(4):CD011792.
  6. 6.Haridas B, Chuang DT, Nei M, et al. Sudden unexpected death in epilepsy: pathogenesis, risk factors, and prevention. Semin Neurol. 2022;42(5):658-664.
  7. 7.DeGiorgio CM, Curtis A, Hertling D, et al. Sudden unexpected death in epilepsy: risk factors, biomarkers, and prevention. Acta Neurol Scand. 2019;139(3):220-230.
  8. 8.Shorvon S, Tomson T. Sudden unexpected death in epilepsy. Lancet. 2011;378(9808):2028-2038.
  9. 9.O’Neal TB, Shrestha S, Singh H, et al. Sudden unexpected death in epilepsy. Neurol Int. 2022;14(3):600-613.
  10. 10.Gavvala JR, Schuele SU. New-onset seizure in adults and adolescents: a review. JAMA. 2016;316(24):2657-2668.
  11. 11.Duñabeitia I, Bidaurrazaga-Letona I, Diz JC, et al. Effects of physical exercise in people with epilepsy: a systematic review and meta-analysis. Epilepsy Behav. 2022;137:108959.
  12. 12.Stirling RE, Hidajat CM, Grayden DB, et al. Sleep and seizure risk in epilepsy: bed and wake times are more important than sleep duration. Brain. 2023;146(7):2803-2813.
  13. 13.Smith PEM. Initial management of seizure in adults. N Engl J Med. 2021;385(3):251-263.
  14. 14.US Equal Employment Opportunity Commission. Epilepsy in the workplace and the ADA. https://www.eeoc.gov/laws/guidance/epilepsy-workplace-and-ada​
  15. 15.Epilepsy Foundation. Driving laws: driver information by state. https://www.epilepsy.com/lifestyle/driving-and-transportation/laws​
  16. 16.Bensalem-Owen MK. Sexual and reproductive health in the management of epilepsy. Continuum (Minneap Minn). 2025;31(1):214-231.
  17. 17.Razaz N, Igland J, Bjørk MH, et al. Risk of perinatal and maternal morbidity and mortality among pregnant women with epilepsy. JAMA Neurol. 2024;81(9):985-995.
  18. 18.Asadi-Pooya AA, Johannessen Landmark C, Mirzaei Damabi N, et al. Interactions between antiseizure medications and foods and drinks: a systematic review. Epilepsia Open. 2024;9(2):475-485.
  19. 19.Clouatre E, Pinto R, Banfield J, et al. Incidence of hot tap water scalds after the introduction of regulations in Ontario. J Burn Care Res. 2013;34(2):243-248.
  20. 20.Pack AM, Oskoui M, Roberson SW, et al. Teratogenesis, perinatal, and neurodevelopmental outcomes after in utero exposure to anti-seizure medication. Epilepsy Curr. 2025;26(1):64-84.
  21. 21.Shankar R, Ashby S, McLean B, et al. Bridging the gap of risk communication and management using the SUDEP and seizure safety checklist. Epilepsy Behav. 2020;103:106419.
  22. 22.Park SP, Kwon SH. Cognitive effects of antiepileptic drugs. J Clin Neurol. 2008;4(3):99-106.
  23. 23.Samsonsen C, Myklebust H, Strindler T, et al. The seizure precipitating effect of alcohol: a prospective observational cross-over study. Epilepsy Res. 2018;143:82-89.
  24. 24.Epilepsy Foundation. Staying safe with exercise and sports. https://www.epilepsy.com/preparedness-safety/staying-safe/exercise-sports​
  25. 25.Epilepsy Association. Is It safe to consume caffeine with epilepsy?. https://www.epilepsyassociation.com/epilepsyu/is-it-safe-to-consume-caffeine-with-epilepsy​
  26. 26.Asadi-Pooya AA, Zeraatpisheh Z, Rostaminejad M, et al. Caffeinated drinks, fruit juices, and epilepsy: a systematic review. Acta Neurol Scand. 2022;145(2):127-138.
  27. 27.Panayiotopoulos CP. Chapter 13, reflex seizures and reflex epilepsies. https://www.ncbi.nlm.nih.gov/books/NBK2596/​
  28. 28.Smart C, Page G, Shankar R, et al. Keep safe: the when, why and how of epilepsy risk communication. Seizure. 2020;78:136-149.
  29. 29.Epilepsy Foundation. Seizure action plans. https://www.epilepsy.com/preparedness-safety/action-plans​
  30. 30.Epilepsy Foundation. Safety at home. https://www.epilepsy.com/preparedness-safety/staying-safe/safety-home​
  31. 31.Epilepsy Alliance America. Seizure safety tips: at home. https://epilepsyallianceamerica.org/seizure-safety/seizure-safety-tips-at-home/​
  32. 32.Wo MC, Lim KS, Choo WY, et al. Employability in people with epilepsy: a systematic review. Epilepsy Res. 2015;116:67-78.
  33. 33.Tran EM, Lee JE. Reporting requirements, confidentiality, and legal immunity for physicians who report medically impaired drivers. JAMA Netw Open. 2024;7(1):e2350495.
  34. 34.Asadi-Pooya AA, Zeraatpisheh Z, Barzegar Z, et al. Driving restrictions in patients with seizures: a review of the regulations from the English-speaking nations. Epilepsy Behav. 2022;135:108888.
  35. 35.Tolchin B, Krauss GL, Spanaki MV, et al. Seizures, driver licensure, and medical reporting update: an AAN position statement. Neurology. 2025;104(7):e213459.
  36. 36.Morrell MJ. Epilepsy in women. Am Fam Physician. 2002;66(8):1489-1494.
  37. 37.Olalere O, Tariq S, Ajijola O, et al. Associations between epileptic seizures in pregnancy and adverse pregnancy outcomes: s systematic review and meta-analysis. PLoS Med. 2025;22(10):e1004580.
  38. 38.Vegrim HM, Dreier JW, Alvestad S, et al. Cancer risk in children of mothers with epilepsy and high-dose folic acid use during pregnancy. JAMA Neurol. 2022;79(11):1130-1138.

Current edition

Seizure Disorders in Adults

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.